$1.98
-0.10 (-4.81%)
Open$2.01
Previous Close$2.08
Day High$2.22
Day Low$1.94
52W High$9.50
52W Low$2.07
Volume—
Avg Volume103.3K
Market Cap69.48M
P/E Ratio—
EPS$-18.03
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+1,015.2% upside
Current
$1.98
$1.98
Target
$22.08
$22.08
$13.69
$22.08 avg
$22.84
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.10M | 11.96M | 10.98M |
| Net Income | 3.15M | 2.42M | 2.50M |
| Profit Margin | 26.0% | 20.2% | 22.8% |
| EBITDA | 4.53M | 4.37M | 3.74M |
| Free Cash Flow | 1.56M | 1.43M | 1.67M |
| Rev Growth | +0.7% | +19.7% | +24.9% |
| Debt/Equity | 0.93 | 0.73 | 0.93 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |